CROs/Service Providers

Initial results from Dana-Farber Cancer Institute personalized neoantigen vaccine published

Friday, July 7, 2017

Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, has announced the publication of an article in Nature presenting initial feasibility, safety, immunogenicity and clinical outcomes for a personalized neoantigen vaccine in patients with adjuvant melanoma. The article entitled ‘An immunogenic personal neoantigen vaccine for patients with melanoma’ (DOI 10.1038/nature22991) demonstrates the validity of the neoantigen vaccine approach as an effective immunotherapy.

[Read More]

INC Research launches Psychiatry Catalyst Site Network

Thursday, July 6, 2017

INC Research Holdings, Inc., a leading, global phase I to IV contract research organization, has announced the launch of the Company’s Psychiatry Catalyst Site Network as part of its Catalyst program introduced in 2016 to strengthen collaborations with clinical research sites worldwide. The ultimate goal of the program is to enhance patient focus and optimize study delivery to drive improved predictability and increased efficiency for customers.  INC selected 32 high-performing clinical research sites to participate in the initial launch of the Psychiatry Catalyst Site Network, which was formed to respond to the rapid growth and strong pipeline of psychiatric studies. The Psychiatry Catalyst Site Network joins INC’s existing networks in place in support of Oncology and Vaccine clinical research.

[Read More]

Interleukin Genetics to reduce workforce

Wednesday, July 5, 2017

Interleukin Genetics, Inc. has announced that it will pursue strategic alternatives for the Company and will reduce the Company’s workforce by five employees (63%) as part of a plan to reduce operating costs.

“While this decision was extremely difficult, it is important to preserve capital as we assess our options,” said Mark Carbeau, Chief Executive Officer of Interleukin Genetics. “I and the other Board members are personally grateful to our departing employees and the exceptional team members throughout the history of the Company who have advanced the contributions that Interleukin Genetics has made to precision medicine and to the advancement of inflammation science broadly.” 

[Read More]

CROS NT launches CROScheck for ICH GCP E6(R2) Guidelines

Wednesday, June 28, 2017

CROS NT, a global CRO, announced CROScheck, a clinical trial solution to deliver sponsors the biometrics oversight needed to assess data integrity from multiple sites. By incorporating data management and statistical methodology along with technology, sponsors can take a modular or full risk-based approach.

[Read More]

inVentiv, Medidata partner to expand use of patient-centered technology

Wednesday, June 28, 2017

Medidata, a global provider of cloud-based technology and data analytics for clinical research, and inVentiv Health, a biopharmaceutical professional services company,  announced a multi-year partnership to bring patient-centric technology and leading clinical trial expertise to the biopharmaceutical industry. The partnership will broaden the reach of Medidata’s electronic informed consent (eConsent) technology, Medidata Enroll, to patients, sites and biopharmaceutical clients worldwide.

[Read More]

Parexel launches Connected Journey of newly integrated data-driven services

Monday, June 19, 2017

As life science companies increasingly seek to gain insights from diverse data sources to make drug development more efficient and effective, Parexel International, a global biopharmaceutical services provider, is launching its Connected Journey of data-driven services. This newly integrated network, powered by PAREXEL Analytics capabilities, combines Parexel’s technology, processes and expertise to deliver critical intelligence supporting clinical development and commercialization.  

[Read More]